Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study | Zendy

Viswanathan Mohan | Zendy; Vineeth Varanasi | Zendy; Anit Singh | Zendy; Marcela F. Pasetti | Zendy; Myron M. Levine | Zendy; Ramasamy Venkatesan | Zendy; Krishna M. Ella | Zendy

Open Access

Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study

Author(s) -

Viswanathan Mohan,

Vineeth Varanasi,

Anit Singh,

Marcela F. Pasetti,

Myron M. Levine,

Ramasamy Venkatesan,

Krishna M. Ella

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ295

Subject(s) - medicine , typhoid fever , toxoid , immunogenicity , tetanus , conjugate vaccine , typhoid vaccine , vaccination , salmonella typhi , pediatrics , open label , virology , immunology , randomized controlled trial , antigen , biochemistry , chemistry , escherichia coli , gene

Enteric fever caused by Salmonella Typhi remains a major public health problem in developing countries. Typbar-TCV is a single-dose typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine for persons ≥6 months of age.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research